The grant will aid GeNO to build a research partnership with Steward St. Elizabeth’s Medical Center to study the physiological performance and biocompatibility of the GeNO liquid source (N2O4) delivery system for the delivery of inhaled NO compared with the GeNO gas cartridge system (which converts NO2) in a porcine model of acute respiratory failure.

GeNO founder and president David Fine said this grant will help GeNO add to the body of research behind their technology so that they can better understand the optimal way to deliver ultrapure nitric oxide to patients.

The product is currently in two Phase 2 trials as one in a pilot study in pulmonary arterial hypertension (PAH) to obtain preliminary safety and feasibility data from short term (15 minute) administration of inhaled nitric oxide.

The second dose-escalation trial for the treatment of pulmonary hypertension in patients with PAH and pulmonary hypertension secondary to idiopathic pulmonary fibrosis (PH-IPF).